Germline mutations in the gene encoding the tumour suppressor E-cadherin (CDH1) are the underlying genetic defect responsible for hereditary diffuse gastric cancer (HDGC). A remarkably high percentage (B80%) of CDH1 mutations in HDGC patients and carriers generate premature termination codons (PTCs). Here, we examined whether CDH1 transcripts harbouring PTCs are downregulated by nonsense-mediated decay (NMD), an RNA surveillance pathway that degrades PTC-bearing transcripts. Using an allele-specific expression (ASE) assay to differentiate between mutated and wild-type CDH1 alleles, we found that PTC-bearing CDH1 mRNAs are strongly downregulated in normal gastric tissue from several CDH1 mutation carriers. We show that NMD is responsible for this robust downregulation, as CDH1 transcripts harbouring PTCs in the KATO-III gastric tumour cell line were upregulated in response to protein synthesis inhibitors or depletion of the NMD factors UPF1 and eIF4AIII. Analysis of HDGC patients harbouring CDH1 alleles with PTCs at a wide variety of different positions indicates an association of their predicted ability to induce NMD and an earlier age of onset of gastric cancer. This suggests that NMD may be detrimental for HDGC patients and therefore NMD is a potentially useful therapeutic target for CDH1 mutation carriers. Oncogene (2008) 27, 4255-4260; doi:10.1038/onc.2008 published online 21 April 2008 Keywords: NMD; E-cadherin; CDH1; gastric cancer; HDGC; KATO-III E-cadherin is an adhesion molecule that acts as a tumour suppressor protein by inhibiting tumour cell invasion and metastasis, as a result of its ability to mediate cell-to-cell adhesion (Suriano et al., 2003) . Germline mutations in the E-cadherin gene (CDH1) are the underlying genetic defect responsible for hereditary diffuse gastric cancer (HDGC; OMIM No. 137215), an autosomal dominant syndrome characterized by high susceptibility to early onset diffuse gastric carcinomas (Guilford et al., 1998) . Heterozygous carriers of E-cadherin germline mutations frequently remain asymptomatic at least until the second decade of life, when inactivation of the remaining wild-type allele of the CDH1 gene occurs (Oliveira et al., 2004) . This two hit inactivation mechanism is believed to determine the initiation of diffuse gastric cancer, consistent with the two-hit inactivation model proposed by Knudson (1971) . Interestingly, the vast majority of such germline CDH1 mutations (B80%) generate premature termination codons (PTCs) Kaurah et al., 2007) . In this report, we investigated whether PTCs in the CDH1 gene engage nonsense-mediated mRNA decay (NMD), a conserved mRNA surveillance mechanism that typically degrades mRNAs harbouring PTCs. The NMD response in mammals discriminates normal stop codons from PTCs using the exon junction complex (EJC), a set of proteins recruited to mRNAs near exon-exon junctions after RNA splicing (Chang et al., 2007) . Most normal transcripts escape NMD since the stop codon is in the final exon and hence EJCs are only deposited upstream the stop codon, permitting the ribosome to displace them. In contrast, an aberrant transcript harbouring a stop codon in an internal exon (where most PTCs reside) will have at least one EJC downstream, thereby triggering NMD (Chang et al., 2007) .
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Evidence suggests that NMD modulates the phenotype of numerous diseases (Holbrook et al., 2004; Wilkinson, 2005) . In some diseases, NMD appears to reduce the severity of the phenotype by downregulating the expression of truncated proteins with dominantnegative activity (for example, in neurological syndromes caused by SOX10 deficiency, b-thalassemia, osteogenesis imperfecta and Marfan syndrome). In other diseases, NMD appears to increase disease severity because of haploinsufficiency by degrading truncated protein retaining some normal function (for example, in cystic fibrosis, ataxia-telangiectasia-like disorder and Duchenne muscular dystrophy). In our study, we examined the role of NMD in the phenotype of HDGC patients caused by truncated mutations in the CDH1 gene.
To test whether NMD downregulates truncated CDH1 transcripts, we performed allele-specific expression (ASE) analysis on normal gastric mucosa from six asymptomatic individuals, belonging to five different HDGC families carrying five different truncating CDH1 mutations. Four of these mutations generate a PTC that has at least one exon-exon junction downstream (in the NMD competent region) and thus we predicted that transcripts harbouring these mutations would be downregulated by NMD. The fifth mutation generates a PTC in the last exon (in the NMD incompetent region) and hence we predicted it would not trigger NMD, because there would not be an EJC downstream of this stop codon.
We first examined an individual with a nonsense mutation at position 283 (C>T), which generates a PTC at codon 95 in exon 3 (Dussaulx-Garin et al., 2001) . ASE analyses were performed using Q-SnapShot, a quantitative fluorescent single-nucleotide extension assay that measures expression by the rate of incorporation of fluorescent dideoxy-nucleotides at polymorphic/ mutated sites (Carrel and Willard, 2005) . This analysis demonstrated that the carrier with this mutation had B14-fold less expression of the mutant allele compared with the wild-type (PTCÀ) allele ( Figure 1a) . We next examined a carrier of mutation 1137G>A, which is in the exon 8 splice donor site, and leads to the generation of an alternatively spliced transcript harbouring a PTC in codon 386 (Frebourg et al., 2006) . Three independent families have been described to carry this 1137G>A Figure 1 CDH1 ASE in normal gastric tissue of CDH1 mutation carriers. Patient's biological material was obtained with informed consent. RNA was isolated from fresh tissue in B, C, D and E with TRIzol (Invitrogen, Carlsbad, CA, USA) and from paraffin embedded tissue in A and F with PureScript RNA Purification System (Gentra, Minneapolis, MN, USA), following the manufacture's protocol. 1 mg of total RNA was reversed transcribed using SuperScript (Invitrogen). Flanking primers were designed for each mutation/polymorphism and Q-SnapShots were performed using PCR products with a 310ABI sequencer following manufacturer's protocol. Specific primer sequences were used for ASE determination, through the rate of incorporation of fluorescent dideoxynucleotides at polymorphic/mutated sites: (a) 283C>T (mutation site); (b) 1137G>A; (c and d) 1135del8ins5 (CDH1 2076T>C SNP to differentiate mutated and wild-type allele expression); (e) 2061delTG (mutation site); (f) 2398delC (mutation site). Q-SnapShot measurement of relative expression of the PTC þ allele, for each individual, is indicated as the ratio with the wild-type allele (gray bars on the right side of the figure). Transparent peak area represents the expression of the WT (PTCÀ) allele and the full black peak represents PTC þ allele. Exon number and location of PTCs in the CDH1 gene are represented in the schematic figure on the left. Note: Every primer sequence will be available upon request. Experiments performed in triplicate. ASE, allele-specific expression; PTC, premature termination codon; WT, wild type. mutation (Kaurah et al., 2007) . ASE analysis revealed that the PTC-bearing (PTC þ ) mutant allele was Bnine-fold less expressed than the PTCÀ allele in the asymptomatic carrier we analyzed (Figure 1b) . We also examined the effect of another mutation (1135de-l8ins5) that generates a PTC at codon 386 (Oliveira et al., 2004) . We found that two individuals from a family harbouring this deletion had reduced expression of the PTC þ allele (4.8-fold and 7.7-fold) relative to the PTCÀ allele (Figures 1c and d) . The fourth mutation we tested was 2061delTG, which generates a PTC at codon 688 in exon 13 (Kaurah et al., 2007) . ASE analysis of normal gastric tissue from an asymptomatic carrier of this mutation demonstrated that the PTC þ allele was reduced in expression by B6-fold relative to the PTCÀ allele (Figure 1e ). Finally, we examined a patient carrying a 2398delC mutation, which generates a PTC in the final exon (codon 815) (Kaurah et al., 2007) , and hence would not be predicted to elicit NMD. In agreement with this prediction, ASE analysis demonstrated that the mutant allele was not expressed at lower levels than the wild-type allele (Figure 1f) .
We found that the mRNAs harbouring PTCs located at the predicted NMD competent region were in fact expressed at a lower abundance compared with the wild type, albeit at different levels. Differential decay of frameshift mutation-derived mRNAs has been demonstrated before (El-Bchiri et al., 2005) . Interestingly, the mRNA carrying the PTC 815 in the predicted NMD incompetent region was not degraded, but on the contrary, was 4-5-fold more abundant than the wildtype. It is possible that this result actually indicates not only insensitivity of the mutated gene to NMD, but also decreased expression of the wild-type allele as result of a second hit event.
To assess whether NMD is responsible for the downregulation of mutant PTC-bearing CDH1 transcripts, we used the KATO-III cell line. This diffuse gastric tumour cell line was previously reported to harbour a splice-site mutation in the CDH1 exon 7 splice donor (1008G>A), leading to the generation of alternatively spliced CDH1 transcripts containing PTCs (Oda et al., 1994) . We first performed a complete characterization of CDH1 genomic sequences and RNA transcripts in the KATO-III cell line. Short tandem repeat analysis with amelogenin and 15 single nucleotide polymorphisms demonstrated that the KATO-III cell line cultured for our studies exactly matched the KATO-III DNA profile provided by the American Type Culture Collection (www.atcc.org) (data not shown). DNA sequencing of the CDH1 exon sequences and exon-intron boundaries detected the previously reported 1008G>A mutation and also demonstrated that KATO-III cells harbour a wild-type allele of CDH1 (Figure 2a ). Cloning and sequencing of CDH1 cDNA identified three alternatively spliced PTCbearing species harbouring different lengths of IVS7 (Figure 2b) .
To determine whether the alternatively spliced PTCbearing CDH1 transcripts are downregulated by NMD, we examined the effect of the protein synthesis inhibitors cycloheximide and puromycin on these cells. These two protein synthesis inhibitors have previously been shown to reverse NMD and upregulate PTC þ transcripts (Carter et al., 1995) by virtue of the fact that NMD requires protein synthesis to recognize PTCs (Chang et al., 2007) . To evaluate whether NMD selectively reduces the level of PTC þ and not PTCÀ CDH1 transcripts, we distinguished between these two classes of transcripts using radioactive reverse transcriptase PCR analysis on polyacrylamide gels. We chose this approach because it permits bands to be analysed after few PCR cycles (before components become limiting), allowing for quantitative analysis. This analysis demonstrated that cycloheximide and puromycin selectively upregulated the three PTC þ transcripts (harbouring PTCs at codons 351, 357 and 374) but not the PTCÀ (wild-type) transcript (Figures 2c and d) .
To definitively verify the role of NMD in downregulating PTC þ CDH1 transcripts, we used RNAi to deplete the levels two NMD factors known to be essential for NMD: (i) the RNA helicase UPF1; and (ii) the RNA-binding anchor of the EJC, eIF4AIII (Chang et al., 2007) . We found that siRNAs targeting these two factors decreased the level of their corresponding mRNAs (Figure 2e ) and protein (Figure 2f ), and significantly increased the level of CDH1 mRNA in KATO-III cells, indicating that NMD was reversed (Figure 2g ).
Our finding that CDH1 truncated transcripts are downregulated by NMD is interesting in light of the fact that an extremely high percentage (B80%) of CDH1 mutations in HDGC patients generate PTCs . This suggested the hypothesis that rather than having a protective role, NMD may promote disease in CDH1 mutation carriers. To assess this possibility, we analyzed the medical data from a large set of published HDGC families (a total of 264 patients) carrying truncating germline mutations Kaurah et al., 2007) in both NMD competent and incompetent regions of the CDH1 gene (Figure 3a ). This analysis revealed that there is a significant association (P ¼ 0.03) between the ability to induce NMD and the age of onset of gastric cancer (Figure 3b ). Patients carrying PTCs in the NMD competent region developed cancer earlier (Figure 3b , left panel) than patients carrying PTCs in the NMD incompetent region (Figure 3b, right panel) . Supporting this notion, a previous study reported four families carrying the 2398delC mutation (located in the NMD incompetent region) had a cumulative risk of acquiring gastric cancer of only 40% for men and 63% for women, which was considerably lower than for HDGC patients in general: 67% for men and 83% for women (Kaurah et al., 2007) .
The association of predicted NMD activity with earlier age of onset of gastric cancer, as well as the observation of lower cumulative risk in patients harbouring a CDH1 mutation that escapes NMD, suggests that NMD may have a detrimental effect on the clinical progression of HDGC. The simplest explanation for this is that after inactivation of the CDH1 wild-type allele by a second-hit event, NMD causes haploinsuffiency by decreasing the level of transcripts carrying PTCs in the NMD competent region of the gene, since such transcripts (especially the more COOH-terminal truncations) probably encode mutated but still functional E-cadherin proteins that retain tumour suppressor activity. In agreement with this, it has previously been shown that truncated E-cadherin molecules lacking the COOH-terminal region retain partial function (Sasaki et al., 2000) .
In the future, it will be important to determine whether truncated E-cadherin proteins generated by PTCs found in CDH1 mutation carriers retain partial tumour suppressor function. This information will be critical to determine the value of inhibiting NMD in HDGC patients as a means to treat or reduce the risk of diffuse gastric carcinoma. -103) ). Cells were cultured in RPMI 1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin (Gibco, Grand Island, NY, USA) in a 5% CO 2 incubator at 37 1C. RNA was extracted as described in figure 1 and 1 mg reversed transcribed with iScript cDNA Synthesis kit (BioRad, Hercules, CA, USA). High molecular weight DNA was isolated using standard methods. (a) CDH1 exon 7 donor splice site sequencing analysis showing a heterozygous G to A transition at nucleotide 1008. (b) Schematic representation of E-cadherin transcripts identified in KATO-III. KATO-III cDNA was PCR-amplified with primers (shown below the schematics as horizontal bars) flanking the 1008G>A mutation, the PCR product was cloned and individual colonies sequenced. (c) E-cadherin transcript-specific expression in KATO-III after treatment with protein synthesis inhibitors cycloheximide (100 mg ml À1 4 h) and puromycin (300 mg ml À1 4 h). Flanking primers specific to KATO-III CDH1 transcripts were end-labeled with [g 32 P]-ATP using T4 polynucleotide kinase (New England BioLabs, Beverly, MA, USA). Low-cycle (18) E-cadherin [g 32 P] end-labeled PCR was performed in no treated, CHX-and puro-treated samples and products were run on 10% acrylamide gels. (d) Quantification of three independent E-cadherin [g 32 P] end-labeled PCRs. Quantification was performed in a STORM 820 phosphoimager (Amersham Biosciences, Piscataway, NJ, USA). (e and f) Knockdown of the NMD factors UPF1 and eIF4AIII, and the luciferase control. 50 nM of specific siRNA was transfected using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) protocol. siRNA oligonucleotides were purchased from Ambion, TX, USA. Protein and RNA isolation was performed 48 h after transfection. RNA was reverse transcribed as described earlier. siRNA-mediated depletion of NMD factors was evaluated by real-time PCR (e) and western blot (f). (g) Real-time PCR evaluation of E-cadherin expression in KATO-III cells depleted of NMD factors. *t-tests with P-value o0.05 were considered significant. Note: Every primer and siRNA sequence will be available upon request. Experiments performed in triplicate. CHX, cycloheximide; puro, puromycin; FBS, fetal bovine serum. NMD downregulates aberrant E-cadherin mRNA R Karam et al
